Precision BioSciences, Inc. (DTIL)

US — Healthcare Sector
Peers: XFOR  ABOS  INZY  TERN  DAWN  ELDN  HOOK  MREO  GRTX  PASG  BDTX  TCRR  HARP  ALEC  STOK  PLRX  DYN  CYTK  RVMD 

Automate Your Wheel Strategy on DTIL

With Tiblio's Option Bot, you can configure your own wheel strategy including DTIL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol DTIL
  • Rev/Share 5.5037
  • Book/Share 5.3096
  • PB 0.9662
  • Debt/Equity 0.0277
  • CurrentRatio 6.6249
  • ROIC -0.3888

 

  • MktCap 56882640.0
  • FreeCF/Share -6.322
  • PFCF -0.9683
  • PE -2.1681
  • Debt/Assets 0.011
  • DivYield 0
  • ROE -0.3585

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade DTIL BMO Capital Markets Market Perform Outperform -- $34 Jan. 10, 2025

News

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
DTIL
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative

Precision BioSciences (DTIL) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.35 per share a year ago.

Read More
image for news Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
DTIL
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (.

Read More
image for news Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
DTIL
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will present initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV program for the treatment of chronic hepatitis B during a late breaking poster presentation at the European Association for the Study of the Liver.

Read More
image for news Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
DTIL
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that five abstracts detailing Precision's wholly owned or partnered programs have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 13-17,.

Read More
image for news Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
DTIL
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

Read More
image for news DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
DTIL
Published: February 19, 2025 by: Benzinga
Sentiment: Positive

On Wednesday, Precision BioSciences, Inc. DTIL revealed initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.

Read More
image for news Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

About Precision BioSciences, Inc. (DTIL)

  • IPO Date 2019-03-28
  • Website https://www.precisionbiosciences.com
  • Industry Biotechnology
  • CEO Mr. Michael Amoroso
  • Employees 108

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.